Women who smoke cigarettes and who are infected with high levels of human papillomavirus type 16 (HPV-16) increase their risk of cervical cancer as much as 27-fold, according to a Swedish study, which is one of the largest to date on the subject.
Women who smoke cigarettes and who are infected with high levels of human papillomavirus type 16 (HPV-16) increase their risk of cervical cancer as much as 27-fold, according to a Swedish study, which is one of the largest to date on the subject.
The researchers found that women who are positive for HPV-16 on their first smear and who smoke are 14 times more likely to develop cervical cancer in situ (CIS) than HPV-16–negative smokers, but only six times more likely to develop the disease than HPV-16–positive nonsmokers. HPV-16–positive smokers with a high viral load at the time of their first smear were at 27 times the risk of HPV-16–negative smokers, while nonsmoking women with a high HPV-16 load had only 6 times the risk of HPV-16–negative nonsmokers.
Gunnell AS, Tran TN, Torrång A, et al. Synergy between cigarette smoking an human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006;15:2141-2147.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More